Clinical trial · no report yet · Phase 3
RASolute 304
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- NCT07252232 ↗
- Recruiting
- Revolution Medicines, Inc.
- 9 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| Podcasts | 3 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma (PDAC); Resected Pancreatic Adenocarcinoma
- Interventions
- daraxonrasib
- Arms
- daraxonrasib · Experimental
- SOC Observation · No intervention
- Enrollment
- 500 (estimated)
- Primary outcomes
- Disease-Free Survival (DFS) per Investigator
- Sponsor
- Revolution Medicines, Inc.
- Start
- Dec 15, 2025
- Primary completion
- May 10, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07252232 · updated Sep 23, 2026